18F synapsin 2 - Synektik
Alternative Names: 18F-labelled tracer SYN2 - SynektikLatest Information Update: 01 Jun 2023
At a glance
- Originator Synektik S.A
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Coronary artery disease
Most Recent Events
- 23 Feb 2023 Synektik completes the phase I/II SAFER trial in Coronary artery disease in Poland (EudraCT2019-003087-43)
- 12 Jan 2021 Phase-I/II clinical trials in Coronary artery disease (Diagnosis) in Poland (IV) (EudraCT2019-003087-43)
- 12 Jan 2021 Preclinical trials in Coronary artery disease (Diagnosis) in Poland (IV) before January 2021